Showing results (271-280 of 289) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies CommitteeGhada Algwaiz, Mahmoud Aljurf, Mickey Koh, et al.
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Blood|July 31, 2008
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee, Manisha Kukreja, Tao Wang, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2017
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for ProphylaxisMuna Qayed, Tao Wang, Michael T Hemmer, et al.
Blood Advances|July 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman, Waleska S Pérez, Hillard M Lazarus, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Pageof 29